Analysis of the Use of Chinese Proprietary Medicines in the Prescriptions of Acute Upper Respiratory Tract Infection in a Hospital from January to June 2021

Qin Tao, Qin Tao, Jingyue Yu, Xueqin Chen, Huiling Liao, Ling Huang, Liu Yang, Yongquan Lai, Haihong Fang

2022

Abstract

Objective To provide a basic reference for the rational use of medicines for patients in the clinic and improve the safety and reliability of Chinese proprietary medicines in treating acute upper respiratory tract infections (URTI) in our hospital and trace the causes of the improper use of medicines. Methods We extracted the outpatient prescriptions for URTI from January to June 2021, and analyzed the basic information of these prescriptions, such as the percentage and amounts of Chinese proprietary medicines and the type of drug combination; the improper prescriptions of Chinese proprietary medicines were confirmed by a pharmacist manual review. Results A total of 2279 prescriptions for patients with acute URTI were reviewed, among which 1939 prescriptions contained Chinese proprietary medicines. Minor patients aged from 1 to 17 years accounted for a large portion of the 1939 prescriptions, and the male-female ratio was 1074:865. Among the 1939 prescriptions, 30 Chinese proprietary medicines were used, and the top three were Kanggan Oral Liquid (20%), Chimonanthus nitens Oliv. Leaf Granules (14.78%), and Lan Qin Oral Liquid (14.09%). The combinations of two and three Chinese proprietary medicines were 381 and 69 cases, respectively. And there were four cases that used four kinds of Chinese proprietary medicines simultaneously. The rate of improper prescriptions was 2.27%. Conclusion From January to June 2021, the use of Chinese proprietary medicines in the outpatient prescriptions for treating acute URTI in our hospital was basically reasonable. However, attention should be paid to the problems existing in improper prescriptions, and the training in TCM theories should be strengthened.

Paper Citation

in Harvard Style

Tao Q., Yu J., Chen X., Liao H., Huang L., Yang L., Lai Y. and Fang H. (2022). Analysis of the Use of Chinese Proprietary Medicines in the Prescriptions of Acute Upper Respiratory Tract Infection in a Hospital from January to June 2021. In Proceedings of the 4th International Conference on Biotechnology and Biomedicine - Volume 1: ICBB; ISBN 978-989-758-637-8, SciTePress, pages 86-91. DOI: 10.5220/0012013700003633

in Bibtex Style

@conference{icbb22,
author={Qin Tao and Jingyue Yu and Xueqin Chen and Huiling Liao and Ling Huang and Liu Yang and Yongquan Lai and Haihong Fang},
title={Analysis of the Use of Chinese Proprietary Medicines in the Prescriptions of Acute Upper Respiratory Tract Infection in a Hospital from January to June 2021},
booktitle={Proceedings of the 4th International Conference on Biotechnology and Biomedicine - Volume 1: ICBB},
year={2022},
pages={86-91},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0012013700003633},
isbn={978-989-758-637-8},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biotechnology and Biomedicine - Volume 1: ICBB
TI - Analysis of the Use of Chinese Proprietary Medicines in the Prescriptions of Acute Upper Respiratory Tract Infection in a Hospital from January to June 2021
SN - 978-989-758-637-8
AU - Tao Q.
AU - Yu J.
AU - Chen X.
AU - Liao H.
AU - Huang L.
AU - Yang L.
AU - Lai Y.
AU - Fang H.
PY - 2022
SP - 86
EP - 91
DO - 10.5220/0012013700003633
PB - SciTePress